Filtered By:
Drug: Fortamet
Therapy: Chemotherapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 195 results found since Jan 2013.
Metformin and Aspirin: Anticancer effects on A549 and PC3 cancer cells and the mechanisms of action
This study aims to investigate the effect of metformin and aspirin and their combination of them on A549 and PC3 cell lines. Metformin and aspirin were investigated separately and in combination on two cancer cell lines, A549 and PC3. The examined groups include the negative control of untreated cells and the positive control of cisplatin and drugs at concentrations of 15, 10, and 20 μg/ mL to investigate the mechanism of oxidative stress factors (reactive oxygen species, lipid peroxidation, Glutathione (GSH)) and apoptosis (lactate dehydrogenase). The results showed that aspirin, metformin, and their combination could af...
Source: Cancer Control - September 4, 2023 Category: Cancer & Oncology Authors: Farzaneh Motafeghi Romina Shahsavari Parham Mortazavi Aysan Babaei Pouria SamadiMojaveri Omid Abed Khojasteh Mohammad Shokrzadeh Source Type: research
Strategy of targeting the tumor microenvironment via inhibition of fibroblast/fibrosis remodeling new era to cancer chemo-immunotherapy resistance
Eur J Pharmacol. 2023 Aug 22:175991. doi: 10.1016/j.ejphar.2023.175991. Online ahead of print.ABSTRACTThe use of repurposing drugs that may have neoplastic and anticancer effects increases the efficiency and decrease resistance to chemotherapy drugs through a biochemical and mechanical transduction mechanisms through modulation of fibroblast/fibrosis remodeling in tumor microenvironment (TME). Interestingly, fibroblast/fibrosis remodeling plays a vital role in mediating cancer metastasis and drug resistance after immune chemotherapy. The most essential hypothesis for induction of chemo-immunotherapy resistance is via activ...
Source: European Journal of Pharmacology - August 24, 2023 Category: Drugs & Pharmacology Authors: Mahboubeh Tajaldini Amirhoushang Poorkhani Taghi Amiriani Amirhossein Amiriani Hossein Javid Parham Aref Farahnazsadat Ahmadi Somayeh Sadani Vahid Khori Source Type: research
Efficacy of metformin in prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients: a randomized controlled trial
Conclusion: The use of metformin in breast cancer patients offered a marked protection against paclitaxel-induced PN, which translated to better patient QoL. Clinical Trial Registration: https://classic.clinicaltrials.gov/ct2/show/NCT05351021, identifier NCT05351021.PMID:37583905 | PMC:PMC10424931 | DOI:10.3389/fphar.2023.1181312
Source: Cancer Control - August 16, 2023 Category: Cancer & Oncology Authors: Hala M Bakry Noha O Mansour Tawfik R ElKhodary Moetaza M Soliman Source Type: research
The metformin immunoregulatory actions in tumor suppression and normal tissues protection
Curr Med Chem. 2023 Jul 3. doi: 10.2174/0929867331666230703143907. Online ahead of print.ABSTRACTThe immune system is the key player in a wide range of responses in normal tissues and tumors to anticancer therapy. Inflammatory and fibrotic responses in normal tissues are the main limitations of chemotherapy, radiotherapy, and also some newer anticancer drugs such as immune checkpoint inhibitors (ICIs). Immune system responses within solid tumors including anti-tumor and tumor-promoting responses can suppress or help tumor growth. Thus, modulation of immune cells and their secretions such as cytokines, growth factors and ep...
Source: Current Medicinal Chemistry - July 5, 2023 Category: Chemistry Authors: Jitendra Gupta Abduladheem Turki Jalil Zahraa Hamzaa Abd Alzahraa Zafar Aminov Fahad Alsaikhan Andr és Alexis Ramírez-Coronel Pushpamala Ramaiah Masoud Najafi Source Type: research
Lower dose of metformin combined with artesunate induced autophagy-dependent apoptosis of glioblastoma by activating ROS-AMPK-mTOR axis
Exp Cell Res. 2023 Jul 1:113691. doi: 10.1016/j.yexcr.2023.113691. Online ahead of print.ABSTRACTGlioblastoma multiform (GBM), one of the most common, aggressive primary brain tumours, demonstrates resistance to radiotherapy and chemotherapy after surgical resection and treatment failure. Metformin (MET) has been shown to suppress the proliferative capacity and invasion ability of GBM cells by activating AMPK and inhibiting mTOR, but the effective dose exceeded the maximum tolerated dose. Artesunate (ART) can exert certain anti-tumour effects by activating the AMPK-mTOR axis and inducing autophagy in tumour cells. Therefor...
Source: Experimental Cell Research - July 3, 2023 Category: Cytology Authors: Wencong Ding Lingxiao Liao Jia Liu Jiaxing Zhao Qiongyan Tang Yongshi Liao Source Type: research
The efficacy of metformin as adjuvant to chemotherapy on IGF levels in non-diabetic female patients with progressive and non-progressive metastatic breast cancer
CONCLUSIONS: Metformin as an adjuvant to chemotherapy in MBC patients had no significant effect on reducing IGF-l levels which promotes the inhibition of the proliferation of BC cells in MBC patients.PMID:37318494 | DOI:10.26355/eurrev_202306_32638
Source: Pharmacological Reviews - June 15, 2023 Category: Drugs & Pharmacology Authors: N M Essa M O Elgendy A Gabr M M Mahmoud A A Alharbi H M Tashkandi H F Salem S Harakeh M S Boshra Source Type: research
Fight Aging! Newsletter, June 12th 2023
In this study, we investigated the effect of NXP032 on neurovascular stabilization through the changes of PECAM-1, PDGFR-β, ZO-1, laminin, and glial cells involved in maintaining the integrity of the blood-brain barrier (BBB) in aged mice. NXP032 was orally administered daily for 8 weeks. Compared to young mice and NXP032-treated mice, 20-month-old mice displayed cognitive impairments in Y-maze and passive avoidance tests. NXP032 treatment contributed to reducing the BBB damage by attenuating the fragmentation of microvessels and reducing PDGFR-β, ZO-1, and laminin expression, thereby mitigating astrocytes and microglia ...
Source: Fight Aging! - June 11, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Stratification of Nontuberculous Mycobacterial Disease Risk in Type 2 Diabetes Based on Metformin Use: a Population-Based Cohort Study in South Korea
Antimicrob Agents Chemother. 2023 May 24:e0167522. doi: 10.1128/aac.01675-22. Online ahead of print.ABSTRACTIn a 1:4 case-control matched analysis of data from a nationwide population-based cohort in South Korea, we evaluated whether metformin use mitigates the risk of nontuberculous mycobacterial disease in patients with type 2 diabetes. Multivariable analysis revealed no significant association of metformin use with a diminished risk for incident nontuberculous mycobacterial disease in patients with type 2 diabetes.PMID:37222618 | DOI:10.1128/aac.01675-22
Source: Antimicrobial Agents and Chemotherapy - May 24, 2023 Category: Microbiology Authors: Hyeon Hwa Kim Seonok Kim Mi Ae Kim Chang Hee Jung Yong Pil Chong Tae Sun Shim Ye-Jee Kim Kyung-Wook Jo Source Type: research
